Loading...
XSHG603538
Market cap384mUSD
Dec 24, Last price  
13.23CNY
1D
0.76%
1Q
24.93%
IPO
-0.18%
Name

Ningbo Menovo Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:603538 chart
P/E
242.08
P/S
2.31
EPS
0.05
Div Yield, %
2.11%
Shrs. gr., 5y
2.59%
Rev. gr., 5y
7.46%
Revenues
1.22b
-16.51%
490,242,539486,647,014501,727,459636,304,955597,166,228578,087,830605,320,593848,961,5181,180,205,3251,193,697,9181,258,147,7101,456,982,4421,216,499,284
Net income
12m
-96.58%
69,334,97460,609,61169,005,22972,730,06077,020,18878,843,43644,677,40096,349,245150,904,871155,962,816142,526,366338,855,53611,585,592
CFO
9m
-96.70%
038,105,479149,207,27875,215,446133,418,224117,244,11880,153,53446,595,179179,751,928251,611,239220,628,551276,951,7469,133,098
Dividend
Jul 15, 20240.02 CNY/sh
Earnings
May 20, 2025

Profile

Ningbo Menovo Pharmaceutical Co., Ltd. research, develops, produces, and sells pharmaceutical products. It offers APIs, intermediates, and formulations for the treatment of cardiovascular, central nervous, respiratory, antitumor, anti-infection, digestive, and geriatric diseases, as well as antiviral. The company was founded in 2004 and is headquartered in Ningbo, China.
URL
http://www.menovopharm.com/
IPO date
Apr 07, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,216,499
-16.51%
1,456,982
15.80%
1,258,148
5.40%
Cost of revenue
1,074,998
1,097,788
959,106
Unusual Expense (Income)
NOPBT
141,501
359,194
299,041
NOPBT Margin
11.63%
24.65%
23.77%
Operating Taxes
(8,225)
16,547
22,222
Tax Rate
4.61%
7.43%
NOPAT
149,726
342,647
276,819
Net income
11,586
-96.58%
338,856
137.75%
142,526
-8.62%
Dividends
(59,242)
(30,263)
Dividend yield
1.34%
0.52%
Proceeds from repurchase of equity
(1,118)
BB yield
0.03%
Debt
Debt current
545,067
497,010
505,035
Long-term debt
775,339
735,941
783,369
Deferred revenue
81,481
70,568
48,670
Other long-term liabilities
86,327
4,846
4,846
Net debt
549,042
140,894
495,239
Cash flow
Cash from operating activities
9,133
276,952
220,629
CAPEX
(219,545)
Cash from investing activities
(323,606)
50,259
Cash from financing activities
54,871
583,149
FCF
(155,778)
402,997
(158,467)
Balance
Cash
724,689
1,009,321
793,165
Long term investments
46,675
82,736
Excess cash
710,539
1,019,208
730,257
Stockholders' equity
1,513,435
1,637,350
1,393,306
Invested Capital
2,866,188
2,359,930
2,527,519
ROIC
5.73%
14.02%
12.35%
ROCE
3.94%
10.32%
8.99%
EV
Common stock shares outstanding
231,712
227,346
216,426
Price
19.12
-25.75%
25.75
1.30%
25.42
-4.36%
Market cap
4,430,330
-24.32%
5,854,154
6.42%
5,501,211
0.70%
EV
5,068,805
6,083,301
6,223,471
EBITDA
259,979
460,957
397,985
EV/EBITDA
19.50
13.20
15.64
Interest
29,980
27,448
27,170
Interest/NOPBT
21.19%
7.64%
9.09%